A PYMNTS Company

Spain: Regulator looks into immunosuppressant drug sector

By  |  April 30, 2019
The CNMC of Spain has announced it is investigating possible anti-competitive practices in the marketing of medicines for the treatment of various autoimmune diseases, performing a surprise dawn raid in the facilities of a laboratory dedicated to the manufacture of these treatments.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The suspicion of presumed monopolistic practices, consisting of an abuse of dominance, would have been conducted through a strategy of limiting the supply of said medications, affecting health services and hospitals throughout the Spanish territory.

    The investigation remains at a preliminary stage, awaiting the results of the inspection carried out on April 23 and 24 . If the abuse is confirmed, the company could face sanctions of up to 10% of their total business volume.
    Full Content: Ibercampus

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.